abs158.txt	checkpoint	immunotherapy	uses	highly	selective	humanized	monoclonal	antibodiesagainst	signals	such	as	programmed	cell	death	receptor	(pd-1)	andprogrammed	ligand	(pd-l1)		by	blocking	these	receptors	and	the	immune	system	can	be	reactivated	to	fight	tumor	foradvanced	non-small	lung	cancer	(nsclc)	has	resulted	in	a	new	paradigm	oftreatment	options	resulting	improved	survival	response	rates	aless	severe	yet	unique	toxicity	profile	when	compared	chemotherapy	pd-1inhibitors	nivolumab	pembrolizumab	pd-l1	inhibitor	atezolizumab	arecurrently	approved	regulatory	authorities	for	treatment	of	advanced	nsclc	this	article	provides	detailed	review	newer	agents	their	mechanism	ofaction	side-effect	therapeutic	indications	current	evidencesupporting	use	management
